Formula I Ovarian Therapy With Hyodeoxycholic Acid
Solution Overview
Problem
Current treatments for ovarian dysfunction diseases, such as hormone replacement therapy and assisted reproduction, have significant side effects and are not effective in the long term, and there is a lack of clear strategies to prevent or delay these conditions.
Innovation Solution
The use of compounds in Formula I, or their pharmaceutically acceptable salts, in combination with hyodeoxycholic acid, to treat or prevent ovarian dysfunction by reducing follicle-stimulating hormone levels and increasing estrogen levels, while alleviating oxidative stress.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy is used to improve estrogen and serum FSH levels, then short-term effectiveness is improved, but side effects and contraindications increase
Solution Approach 1:
The patent changes the chemical parameters of the treatment by using compounds with specific molecular structures (Formula I) that modify hormone levels through different mechanisms than traditional hormone replacement therapy, thereby achieving therapeutic effects with reduced side effects
Solution Approach 2:
The patent employs compounds that act as temporary, targeted interventions rather than long-term hormone replacement, allowing the body to maintain natural hormone regulation while receiving therapeutic support, thus reducing cumulative side effects
2Reliability
If estrogen is used to treat ovarian dysfunction, then short-term hormone levels improve, but long-term curative effect deteriorates and thrombosis risk increases
Solution Approach 1:
The patent uses compounds (Formula I) as intermediary substances that mediate between the need for hormone supplementation and the body's natural regulation systems, providing sustained therapeutic effect without the direct risks of long-term estrogen therapy
Solution Approach 2:
The treatment approach enables periodic restoration of ovarian function through compounds that can be administered in cycles, allowing the ovaries to maintain intermittent function rather than complete dependence on exogenous hormones, thus improving long-term outcomes
3Reliability
If assisted reproductive therapy is used for ovarian dysfunction, then pregnancy outcomes may be achieved, but cost and accessibility deteriorate
Solution Approach 1:
The patent enables the ovaries to self-regulate and resume natural function through compound administration, eliminating the need for complex assisted reproductive technologies and making treatment more accessible and cost-effective
4Adaptability or versatility
If no prevention strategy is implemented, then treatment options remain limited, but disease progression and psychological burden increase
Solution Approach 1:
The patent provides compounds that can be used preventively to protect ovarian function before complete dysfunction occurs, allowing early intervention and maintaining treatment flexibility while reducing the psychological burden of inevitable disease progression
Data Source
AI summary
Use of the active compound in the present disclosure for the prevention or treatment of ovarian dysfunction disease. In particular, the present disclosure relates to the use of a compound shown in Formula I or a pharmaceutically acceptable salt thereof in the treatment or prevention of ovarian dysfunction disease, wherein R1 and R2 are each independently selected from H, C1-C6 alkyl, C1-C6 alkenyl, and C1-C6 alkynyl. The present disclosure also relates to the use of a compound shown in said Formula I or a pharmaceutically acceptable salt thereof, in combination with hyodeoxycholic acid or a pharmaceutically acceptable salt thereof, in the treatment or prevention of ovarian dysfunction disease. The present disclosure also relates to compositions comprising a compound shown in said Formula I or a pharmaceutically acceptable salt thereof and/or hyodeoxycholic acid or a pharmaceutically acceptable salt thereof.



